Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Immune Thrombocytopenia Treatment, COVID, and Other Vaccinations

February 2nd 2022

Physicians share concerns with ITP medications and response to COVID-19 and other vaccinations.

CML: Third-Line Treatment Options for Chronic Myeloid Leukemia

February 2nd 2022

Jorge Cortes, MD, breaks down third-line treatment options for patients who progress with chronic myeloid leukemia.

CML: Challenges and Unmet Needs in Later-Line Therapy

February 2nd 2022

A brief review of the inherent challenges in guiding patients through several lines of therapy for chronic myeloid leukemia.

EU Panel Recommends Avapritinib for Advanced Systemic Mastocytosis

January 31st 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended to expand the current indication for avapritinib to include single-agent use in patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, or mast cell leukemia.

Ramchandren Reviews the Rationale to Further Evaluate CLR 131 in Waldenström Macroglobulinemia

January 31st 2022

Dr Ramchandren discusses current treatment options for patients with Waldenström macroglobulinemia who have limited response to other therapies, the rationale for the expansion cohort of the phase 2 CLOVER-WaM trial evaluating CLR 131 in these patients, and other anticipated research trends in this paradigm.

ASH 2021: Novel Therapy in Acute Lymphocytic Leukemia

January 31st 2022

Expert perspectives on clinical data readouts in acute lymphocytic leukemia from the ASH 2021 annual meeting.

Liso-cel Approaches EU Approval for Relapsed/Refractory DLBCL, PMBCL, and Follicular Lymphoma Grade 3B

January 28th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of lisocabtagene maraleucel for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B following 2 or more lines of systemic therapy.

IKEMA Study in R/R Multiple Myeloma

January 28th 2022

Ola Landgren, MD, PhD, reviews the results and clinical implications of the IKEMA study for patients with relapsed/refractory multiple myeloma.

Updates From the CANDOR Study in R/R Multiple Myeloma

January 28th 2022

Katja Weisel, MD, leads a review of the study design and updated efficacy and safety results of the phase 3 CANDOR study for patients with relapsed/refractory multiple myeloma.

Orca-T Reduces GVHD, Improves GVHD-Free RFS in Posttransplant Setting Across Hematologic Cancers

January 28th 2022

Arpita Gandhi, MD, discusses the background of Orca-T in further detail and how this type of treatment could revolutionize outcomes for patients with serious hematologic malignancies.

Clinical Pearls in the Management of Mantle Cell Lymphoma

January 28th 2022

Closing out their discussion on mantle cell lymphoma, expert panelists share clinical pearls for practicing community physicians.

Optimizing MCL Management: Sequencing and Combination Strategies

January 28th 2022

Panelists use an illustrative clinical case to highlight best practices in sequencing therapy for mantle cell lymphoma and discuss novel combination strategies under investigation.

2-Year OS Improves Over 20 Years in Relapsed Ph+ ALL Post Allogeneic Transplant

January 27th 2022

The 2-year overall survival rate almost doubled between 2000 and 2004 and 2015 and 2019 in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia who had relapsed after allogeneic hematopoietic cell transplant, indicating improvements in patient care overall.

FDA Places Partial Clinical Hold on Trials Examining Magrolimab Plus Azacitidine in MDS, AML, and Myeloid Malignancies

January 27th 2022

The FDA has placed a partial clinical hold on clinical trials evaluating the combination of magrolimab and azacitidine after an apparent imbalance in investigator-reported, suspected unexpected serious adverse reactions observed between study arms.

Debate Regarding Upfront Treatment of Immune Thrombocytopenia

January 26th 2022

ITP experts debate different strategies they use in upfront treatment of ITP.

Treatment of Early Immune Thrombocytopenia (ITP)

January 26th 2022

Drs Bussel and Kessler discuss treatment of early immune thrombocytopenia (ITP).

Selecting Second-Line Therapy for Chronic Myeloid Leukemia

January 26th 2022

Considerations for selecting optimal second-line therapy for chronic myeloid leukemia when a patient progresses.

Dr. Lister on Selecting Patients With Lymphoma for CAR T-Cell Therapy

January 26th 2022

John Lister, MD, discusses selecting patients with lymphoma for CAR T-cell therapy.

Role of Tyrosine Kinase Inhibitors in Treatment of CML

January 26th 2022

Daniel DeAngelo, MD, PhD, highlights the role that tyrosine kinase inhibitors play in the CML treatment paradigm.

Relapsed and Refractory Diffuse Large B-Cell Lymphoma

January 24th 2022

A panel of diffuse large B-cell lymphoma experts discuss patient criteria and treatment selection in relapsed/refractory DLBCL.